Abstract
BackgroundSwitching from the first Tumor Necrosis Factor α inhibitor (TNFi) to a second in rheumatoid arthritis is an effective strategy to decrease disease activity. Especially, when antidrug antibodies (ADA) against...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have